Should You Buy agilon health inc (AGL) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/28
Not a good buy right now for a beginner long-term investor with $50k–$100k and low patience. The stock is a distressed sub-$1 name with deteriorating profitability, multiple fresh class-action headlines, bearish/unstable technicals, and extremely elevated options implied volatility signaling uncertainty. Even if a bounce occurs near support, the risk/reward is not attractive for a long-term, beginner-friendly allocation today.
Technical Analysis
Price is weak and trading near key support. MACD histogram (-0.00744) is below zero and negatively expanding, indicating bearish momentum is strengthening. RSI(6) ~32.6 is near oversold but still not a clear reversal signal (can stay weak in downtrends). Moving averages are converging, consistent with consolidation after a sharp decline rather than a confirmed uptrend. Key levels: S1=0.838 (near current ~0.854 pre-market), S2=0.777; pivot=0.936 is the first meaningful area the stock must reclaim to improve trend, then R1=1.034.
Analyst Ratings and Price Target Trends
Recent trend: analysts have been cutting targets and staying cautious. Bernstein (Dec 4, 2025) cut PT to $0.88 from $1.40 and kept Market Perform, citing high prior-period medical costs and exit costs. Evercore (Nov 5, 2025) cut PT to $0.50 from $1 and kept In Line after weaker-than-expected Q3 and a challenging setup implied by guidance. Jefferies (Dec 18, 2025) highlighted CMS LEAD model as a sector positive but maintained Hold on Agilon. Wall Street pros: potential VBC/ACO policy tailwinds and a sector-turnaround possibility. Cons: execution/medical cost variability, weak results, lowered targets, and headline/legal overhang. Influential/political activity: no recent Congress trading data available; insiders show no significant recent trend (neutral). Intellectia Proprietary Trading Signals: no AI Stock Picker signal today and no recent SwingMax signal, so there is no proprietary tactical confirmation to override the bearish/uncertain setup.
Wall Street analysts forecast AGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGL is 0.98 USD with a low forecast of 0.5 USD and a high forecast of 1.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast AGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGL is 0.98 USD with a low forecast of 0.5 USD and a high forecast of 1.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 0.854
Current: 0.854
